Myopia Control Program

Childhood myopia is progressive. The earlier it starts, the higher it ends — and the higher final prescription is associated with measurable lifetime risks: retinal detachment, myopic maculopathy, glaucoma, cataract. The right treatment, started early enough, can slow that progression by 50–80% in many children.

We fit four evidence-based modalities. Stellest spectacle lenses (FDA-cleared 2025, Essilor) work for most children and require no contact-lens fitting. Orthokeratology (Ortho-K) reshapes the cornea overnight, freeing the child from daytime correction. Low-dose atropine drops (0.025–0.05%) work pharmacologically and can be combined with the others. Multifocal soft contact lenses give myopia control plus daytime correction in one product.

The right modality depends on age, refractive error, axial length, parental routine, and how the child feels about handling lenses. We measure axial length at every visit and report it to parents at each follow-up — the prescription is one signal, but axial length is the better one.